Amarin Corporation

Amarin Corporation Intangible Assets

The Intangible Assets of Amarin Corporation (AMRN) as of Nov 19, 2026 is 13.37 M USD. In the previous year, Intangible Assets was 16.39 M USD — a change of -18.45% (lower).

Intangible Assets

13.37 MUSD

YoY

-18.45%

Last updated:

Intangible Assets of Amarin Corporation is 2025 13.37 M USD. Intangible Assets of Amarin Corporation was 2024 16.39 M USD. It decreases by -18.45% lower compared to the previous year.

The Amarin Corporation Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
7.50 M USD
Jan 1, 2019
15.30 M USD
Jan 1, 2020
13.80 M USD
Jan 1, 2021
23.50 M USD
Jan 1, 2022
21.80 M USD
Jan 1, 2023
19.30 M USD
Jan 1, 2024
16.39 M USD
Jan 1, 2025
13.37 M USD
The Amarin Corporation Intangible Assets history
YEARIntangible AssetsYoY
13.37 MUSD-18.45%
16.39 MUSD-15.10%
19.30 MUSD-11.45%
21.80 MUSD-7.23%
23.50 MUSD+70.29%
13.80 MUSD-9.80%
15.30 MUSD+104.00%
7.50 MUSD-7.41%
8.10 MUSD-7.95%
8.80 MUSD-6.38%
9.40 MUSD-6.93%
10.10 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Intangible Assets of Amarin Corporation is 13.37 M USD in 2025.

Intangible Assets of Amarin Corporation changed from 16.39 M USD to 13.37 M USD, representing a -18.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Amarin Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Amarin Corporation

All Key Metrics — Amarin Corporation